Danaher Third-Quarter Earnings Rise; Pharma R&D Spend Expected to Rebound
The life sciences and diagnostics company posted sales of $6.05 billion and stands to benefit from an increase in pharmaceutical-research investment as tariff uncertainty eases.
Source link
